Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- A/S (Nasdaq: ASND) ...

with Ascendis set to receive a $100 million m - Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

TransCon CNP (navepegritide ... date of the supplemental BLA for SKYTROFA for the treatment of adults with growth hormone deficiency and Ascendis' plans for a U.S. commercial launch, if approved ...

At the heart of the agreement is an exclusive worldwide license to Copenhagen-based Ascendis' TransCon technology ... a long-acting growth hormone for children with growth hormone deficiency.

AIMS To evaluate the effects of discontinuing growth hormone (GH) treatment on energy expenditure and body composition, which might help predict those most likely to benefit from early reintroduction ...

“Ascendis is well-positioned for rapid revenue growth with ... First planned TransCon protein degrader product candidate designed to normalize excess FGF-23 hormone levels for patients with ...

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

“Our expanding TransCon technology platform and partnerships ... BLA for SKYTROFA for the treatment of adults with growth hormone deficiency and Ascendis’ plans for a U.S. commercial launch ...

If you're dealing with hair trouble, from thinning to damage from bleach and styling, your goal may be to prioritize hair growth for longer, healthier locks. Fortunately, there are supplements out ...